1. Gasser T. Genetics of Parkinson’s Disease. J Neurol 2001; 248(10): 833-840.
2. Ahlskog JE. Diagnosis and differential diagnosis of Parkinson’s Disease and Parkinsonism. Parkinsonism Relat Disord 2001; 7(1): 63-70.
3. Przedborski S. Pathogenesis of nigral cell death in Parkinson’s Disease. Parkinsonism Relat Disord 2005; 11(1): S3-S7.
4. Ameisen JC. On the origin, evolution, and nature of programmed cell death: a timeline of four billion years. Cell Death Differ 2002; 9(4): 367-393.
5. Philchenkov A. Caspases: potential targets for regulating cell death. J Cell Mol Med 2004; 8(4): 432-444.
6. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Molec Cell Biol 2004; 5(11): 897-907.
7. Green DR. Apoptotic pathways: ten minutes to dead. Cell 2005; 121(5): 671-674.
8. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000; 102(1): 1-4.
9. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of APAF-1/Caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91(4): 479-489.
10. Bossy-Wetzel E, Green DR. Caspases induce cytochrome c release from mitochondria by activating cytosolic factors. TJ Biol Chem 1999; 274(25): 17484-17490.
11. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116(2): 205-219.
12. Hirsch EC, Hunot S, Faucheux B, Agid Y. Dopaminergic neurons degenerate by apoptosis in Parkinson’s Disease. Mov Disord 1999; 14(2): 383-384.
13. Banati R, Blunt S, Graeber MB. What does apoptosis have to do with Parkinson’s Disease. Mov Disord 1999; 14(2): 384-385.
14. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain. J Neural Transm 2000; 107(3): 335-341.
15. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s Disease. Proc Natl Acad Sci USA 2001; 98(5): 2837-2842.
16. Hayakawa M, Hayakawa H, Migita M, Shibata M, Tanaka R, Suzuki A, Shimo-Nakanishi Y, Urabe T, Yamada M, Tamayose K, Shimada T, Miura M, Mizuno Y. An AAV-derived APAF-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson’s Disease. Proc Natl Acad Sci USA 2001; 98(19): 10918-10923.
17. Gorman AM, Szegezdi E, Quigney DJ, Samali A. Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells. Biochem Biophys Res Commun 2005; 327(3): 801-810.
18. Biswas SC, Ryu E, Park C, Malagelada C, Greene LA. Puma and p53 play required roles in death evoked in a cellular model of Parkinson’s Disease. Neurochem Res 2005; 30(6-7): 839-845.
19. Perier C, Tieu K, Guégan C, Caspersen C, Jackson-Lewis V, Carelli V, Martinuzzi A, Hirano M, Przedborski S, Vila M. Complex I deficiency primes bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA 2005; 102(52): 19126-19131.
20. Xu J, Zhong N, Wang H, Elias JE, Kim CY, Woldman I, Pifl C, Gygi SP, Geula C, Yankner BA. The Parkinson’s Disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Molec Genet 2005; 14(9): 1231-1241.
21. Petit A, Kawarai T, Paitel E, Sanjo N, Maj M, Scheid M, Chen F, Gu Y, Hasegawa H, Salehi-Rad S, Wang L, Rogaeva E, Fraser P, Robinson B, St George-Hyslop P, Tandon A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson Disease-related mutations. J Biol Chem 2005; 280(40): 34025-34032.
22. Maraganore DM, Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, Krishna Pant PV, Frazer KA, Cox DR, Ballinger DG. High-resolution whole-genome association study of Parkinson Disease. Am J Hum Genet 2005; 77(5): 685-693.
